By Joseph Constance
The pharmaceutical industry has been quick to embrace virtual, or decentralized, clinical trials during the COVID-19 pandemic, looking to technology to keep the business of running clinical trials as close to schedule as possible.
Normally, the use of virtual elements in clinical trials would have appeared gradually, rather slowly, as we are part of an industry that likes to consider change pensively. We usually hesitate to move forward rapidly on big issues.
But drug companies have moved quickly this time to salvage their research and at the same time keep patients safe. The FDA has given the green light for initiating virtual trials amid the crisis. The European Medicines Agency has addressed the issue as well.
With a jolt from COVID-19, virtual trials not only are here to stay, but we can expect to see a more extensive use of virtual elements in trials.
Virtual clinical trials offer a number of advantages to sponsors. They:
Quicken recruitment. Expand recruitment geographically. Improve and expand patient engagement. Potentially deliver verified data quic...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).